Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of valsartan + levoamlodipine in primary mild-to-moderate hypertension inadequately controlled after 4 weeks of monotherapy
CTR20242169Phase 3Active
- Sponsor
- Jiangxi Shimei Pharmaceutical
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of valsartan, Levamlodipine in essential hypertension, sponsored by Jiangxi Shimei Pharmaceutical. Started Aug 2024; status: active.
02
Drugs
valsartanLevamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20242169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242169.